Significance of circulating plasma cells in multiple myeloma.

Abstract:

:The number of circulating plasma cells (CPC) was determined on mononuclear cell preparations after Giemsa (morphology) and light chain staining (immunocytochemistry). Both methods gave reproducible and identical results when CPC were 1% or more. Using this limit, no CPC were observed in MGUS (0/11) and primary amyloidosis (0/2), whereas 45/98 (45.9%) multiple myeloma (MM) pts had > or = 1% CPC. 3/14 pts (21.4%) in stage I, 5/13 pts (38.5%) in stage II, 20/28 pts (71.4%) in stage III, 4/25 pts (16%) at plateau phase, and 13/18 pts (72.2%) at relapse had > or = 1% CPC (p < 0.001). Mean beta-2 microglobulin was 3.77 mg/l and 6.08 mg/l for pts without or with > or = 1% CPC, respectively p = 0.0001). Presence of CPC was also correlated with an higher percentage of bone marrow PC, but not with the number of Ki-67 positive BM-PC, and not with CRP or LDH levels. K/L and Gamma/Alpha CPC isotype ratio showed these cells as monotypic in nearly all pts. The prognostic value could not really be assessed in this study, as only the initial response to therapy was investigated, and the latter failed to give any difference between pts with and without CPC. So, presence of CPC is not an infrequent finding, but is highly related to tumor mass and active disease; in most if not all patients they are monotypic and certainly belong to the malignant clone. Their prognostic value is unclear but under current investigation; CPC are correlated with B-2M level.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Zandecki M,Facon T,Preudhomme C,Canis F,Izydorczyk V,Lovi V,Hammad M,Bauters F,Cosson A

doi

10.3109/10428199409049709

subject

Has Abstract

pub_date

1994-08-01 00:00:00

pages

491-6

issue

5-6

eissn

1042-8194

issn

1029-2403

journal_volume

14

pub_type

杂志文章
  • The role of nuclear medicine in the treatment of non-Hodgkin's lymphoma (NHL).

    abstract::The emergence of radioimmunotherapy (RIT) provides a new therapeutic approach in which monoclonal antibodies directed against tumor-specific antigens are used to target therapeutic radioisotopes to sites of disseminated disease. The target cell is eliminated and adjacent tumor cells, to which antibody has not bound, a...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428140310001616935

    authors: Bischof Delaloye A

    更新日期:2003-01-01 00:00:00

  • A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma.

    abstract::The purpose of this phase 2 study was to determine the activity and safety of six cycles of bendamustine and eight rituximab (RB) as first-line treatment of adult patients with advanced stage non-follicular indolent non-Hodgkin lymphomas (INFL). The primary end-point was the complete response rate (CRR) with expected ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究

    doi:10.3109/10428194.2015.1091934

    authors: Luminari S,Goldaniga M,Cesaretti M,Orsucci L,Tucci A,Pulsoni A,Salvi F,Arcaini L,Carella AM,Tedeschi A,Pinto A,Stelitano C,Baldini L

    更新日期:2016-01-01 00:00:00

  • Pharmacologic prophylaxis regimens for acute graft-versus-host disease: past, present and future.

    abstract::Abstract Acute graft-versus-host disease (GVHD) has compromised and continues to compromise the benefits associated with allogeneic hematopoietic cell transplant to cure malignant and non-malignant diseases. Pharmacologic interventions to prevent GVHD have emerged as a major objective of research in the immunology and...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2012.762978

    authors: Ram R,Storb R

    更新日期:2013-08-01 00:00:00

  • P27 in cell cycle control and cancer.

    abstract::In order to survive, cells need tight control of cell cycle progression. The control mechanisms are often lost in human cancer cells. The cell cycle is driven forward by cyclin-dependent kinases (CDKs). The CDK inhibitors (CKIs) are important regulators of the CDKs. As the name implies, CKIs were initially shown to ne...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428190009053535

    authors: Møller MB

    更新日期:2000-09-01 00:00:00

  • Hepatitis B reactivation in patients positive for hepatitis B surface antigen undergoing autologous hematopoietic cell transplantation.

    abstract::Hepatitis due to reactivation of hepatitis B virus is an important cause of liver-related morbidity and mortality in hepatitis B surface antigen (HBsAg) positive patients undergoing autologous hematopoeitic cell transplantation. With the recent introduction of sensitive serum HBV DNA quantitation assay, the diagnosis ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/1042819031000083343

    authors: Ma SY,Lau GK,Cheng VC,Liang R

    更新日期:2003-08-01 00:00:00

  • Pre-transplant 18FDG-PET predicts outcome in lymphoma patients treated with high-dose sequential chemotherapy followed by autologous stem cell transplantation.

    abstract::We evaluated the prognostic role of 18FDG-PET performed before ASCT in patients affected by lymphoma who underwent high-dose chemotherapy followed by ASCT as first-line treatment for high-risk disease or as second-line or more for relapsed or refractory disease. We retrospectively analyzed 53 consecutive patients, 14 ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190701885545

    authors: Crocchiolo R,Canevari C,Assanelli A,Lunghi F,Tassara M,Stanghellini ML,Clerici D,Landoni C,Servida P,Bernardi M,Peccatori J,Ferreri A,Gianolli L,Bordignon C,Caligaris-Cappio F,Ciceri F,Fazio F

    更新日期:2008-04-01 00:00:00

  • Advances in umbilical cord blood transplant: a summary of the 11th International Cord Blood Symposium, San Francisco, 6-8 June 2013.

    abstract::The 11th International Cord Blood Symposium was devoted to advances in umbilical cord blood (UCB) research and transplant. Results of cord blood transplant (UCB SCT) for congenital storage disease and hemoglobinopathies are encouraging, but UCB SCT may also be useful for older adults with hematologic malignancies, and...

    journal_title:Leukemia & lymphoma

    pub_type:

    doi:10.3109/10428194.2013.837162

    authors: van Besien K

    更新日期:2014-08-01 00:00:00

  • Superior outcome of patients with favorable-risk acute myeloid leukemia using consolidation with autologous stem cell transplantation.

    abstract::Autologous stem cell transplantation (ASCT), intensifying anti-leukemic effects without significant treatment-related mortality (TRM), is particularly appealing in AML with favorable genetic/molecular profile. This study retrospectively evaluated the outcomes of post-remission treatment in consecutive favorable-risk A...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2019.1594214

    authors: Beyar-Katz O,Lavi N,Ringelstein-Harlev S,Henig I,Yehudai-Ofir D,Haddad N,Fineman R,Ofran Y,Nov Y,Sahar D,Moustafa-Hawash N,Rowe JM,Zuckerman T

    更新日期:2019-10-01 00:00:00

  • Primary gastric lymphoma: utility of 18F-fluorodeoxyglucose positron emission tomography-computed tomography for detecting relapse after treatment.

    abstract::The purpose of this study was to evaluate the role of 18F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography-computed tomography (PET-CT) in detecting relapse in patients with primary gastric lymphoma (PGL) post-treatment. Data of 39 previously treated patients with PGL (age: 50.3 ± 13.8 years; male: 24) who ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2012.717694

    authors: Sharma P,Suman SK,Singh H,Sharma A,Bal C,Malhotra A,Kumar R

    更新日期:2013-05-01 00:00:00

  • Fine-Needle Aspiration Cytology and Immunocytochemistry of Abdominal Non-Hodgkin's Lymphomas.

    abstract::The cytomorphology and immunologic characteristics of cells obtained by fine-needle aspiration biopsy of 34 consecutive patients with abdominal lymphomas were analyzed. Nineteen patients had no previous diagnosis, while 15 had previously known or suspected lymphomas. On cytology 21 high-grade and 13 low-intermediate-g...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428198909042461

    authors: Liliemark J,Tani E,Christensson B,Svedmyr E,Skoog L

    更新日期:1989-01-01 00:00:00

  • Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis.

    abstract::Recently, lenalidomide and low dose dexamethasone were found to result in superior overall survival compared to lenalidomide and high dose dexamethasone. The immune suppressive effects of dexamethasone can antagonize lenalidomide immunomodulatory activity and may explain this observation. We conducted a retrospective ...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.3109/10428191003721342

    authors: Baz R,Patel M,Finley-Oliver E,Lebovic D,Hussein MA,Miller KC,Wood M,Sher T,Lee K,Chanan-Khan AA

    更新日期:2010-06-01 00:00:00

  • Characterization of cancer comorbidity prior to allogeneic hematopoietic cell transplantation.

    abstract::Higher comorbidity by the hematopoietic cell transplantation-comorbidity index increases rates of non-relapse mortality (NRM) and impairs survival following allogeneic hematopoietic transplantation. We explored the effects of cancer as a comorbid condition prior to allogeneic transplantation. Among 356 adult transplan...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2018.1493728

    authors: D'Angelo CR,Novitsky B,Mee Lee S,Godley LA,Kline J,Larson RA,Liu H,Odenike O,Stock W,Bishop MR,Artz AS

    更新日期:2019-03-01 00:00:00

  • MicroRNAs and tRNA-derived fragments predict the transformation of myelodysplastic syndromes to acute myeloid leukemia.

    abstract::Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders of the elderly that carry an increased risk of progression to acute myeloid leukemia (AML). Since small non-coding RNAs (sRNAs), including microRNA (miRNAs), act as regulators of cellular differentiation, we hypothesized that changes to sRNAs might be ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2016.1272680

    authors: Guo Y,Strickland SA,Mohan S,Li S,Bosompem A,Vickers KC,Zhao S,Sheng Q,Kim AS

    更新日期:2017-09-01 00:00:00

  • Herbs in hemato-oncological care: an evidence-based review of data on efficacy, safety, and drug interactions.

    abstract::Herbal remedies are clearly a complementary and alternative modality used frequently by patients with hemato-oncological neoplasias during the course of their specific treatment. This review focuses on the potential safety and efficacy of herbs which are either used often or even on a daily basis by patients with hema...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2010.487622

    authors: Ben-Arye E,Attias S,Tadmor T,Schiff E

    更新日期:2010-08-01 00:00:00

  • Low-dose fludarabine with or without darbepoetin alfa in patients with chronic lymphocytic leukemia and comorbidity: primary results of the CLL9 trial of the German CLL Study Group.

    abstract::This study was planned as a phase 3 trial to investigate low-dose fludarabine with or without darbepoetin alfa in older patients with previously untreated or treated chronic lymphocytic leukemia (CLL) and comorbidity. Due to slow recruitment, the study was terminated prematurely after accrual of 97 patients who, on av...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.3109/10428194.2015.1079314

    authors: Goede V,Busch R,Bahlo J,Chataline V,Kremers S,Müller L,Reschke D,Schlag R,Schmidt B,Vehling-Kaiser U,Wedding U,Stilgenbauer S,Hallek M

    更新日期:2016-01-01 00:00:00

  • Dose reductions in ibrutinib therapy are not associated with inferior outcomes in patients with chronic lymphocytic leukemia (CLL).

    abstract::Ibrutinib is a first-in-class small molecule inhibitor that has shown remarkable efficacy in the treatment of CLL. Current guidelines recommend lifelong administration at a fixed daily dose of 420 mg. Data from real-world studies indicate up to 17.5% of patients discontinue ibrutinib due to toxicity. Hypothetically, j...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2018.1554862

    authors: Akhtar OS,Attwood K,Lund I,Hare R,Hernandez-Ilizaliturri FJ,Torka P

    更新日期:2019-07-01 00:00:00

  • Overexpression of phosphorylated p27 Kip1 at threonine 187 may predict outcome in aggressive B-cell lymphomas.

    abstract::Phosphorylation of p27(Kip1) at threonine 187 (pThr187-p27(Kip1)) occurs frequently in the development of human tumors, directing protein polyubiquitination and subsequent proteasomal degradation. We investigated the immunoexpression of p27(Kip1) and pThr187-p27(Kip1) in 126 B-cell lymphomas and their relation to prol...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2011.555026

    authors: Sirinian C,Symeonidis A,Giannakoulas N,Zolota V,Melachrinou M

    更新日期:2011-05-01 00:00:00

  • HIV portends a poor prognosis in myelodysplastic syndromes.

    abstract::Even though HIV is associated with worse prognosis in many malignancies, the clinical course of myelodysplastic syndrome (MDS) in HIV + patients has not been well studied. Determining the clinical presentation and outcomes of MDS in these patients would be important for future diagnostic strategies, as anemia and othe...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2019.1633631

    authors: Kaner JD,Thibaud S,Jasra S,Wang Y,Janakiram M,Sharma A,Sridharan A,Elias H,Polineni R,Assal A,Weiss L,Braunschweig I,Steidl U,Pradhan K,Shastri A,Chaitowitz M,Zingman B,Will B,Mantzaris I,Verma A

    更新日期:2019-12-01 00:00:00

  • In vitro efficacy of known P-glycoprotein modulators compared to droloxifene E and Z: studies on a human T-cell leukemia cell line and their resistant variants.

    abstract::P-glycoprotein(P-gp)- related resistance is one of the major obstacles in treating leukemia patients. Therefore, it is of clinical interest to find new potential modulators and compare their P-gp-modulating efficacy. The present analysis investigated the influence of P-gp modulators, such as verapamil, tamoxifen, drol...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199809057619

    authors: Nüssler V,Pelka-Fleisc R,Gieseler F,Hasmann M,Löser R,Gullis E,Stötzer O,Zwierzina H,Wilmanns W

    更新日期:1998-11-01 00:00:00

  • Ultrastructural features of CD34+ hematopoietic progenitor cells from bone marrow, peripheral blood and umbilical cord blood.

    abstract::Hematopoietic progenitor cells from different sources have been widely characterized, but their ultrastructural morphology has never been described in detail. In this study, imunomagnetically separated CD34+ cells from normal bone marrow (BM), mobilized peripheral blood (PBSC) and human umbilical cord blood (CB) were ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190109099332

    authors: Deliliers GL,Caneva L,Fumiatti R,Servida F,Rebulla P,Lecchi L,De Harven E,Soligo D

    更新日期:2001-08-01 00:00:00

  • Extensive analysis of the T315I substitution and detection of additional ABL mutations in progenitors and primitive stem cell compartment in a patient with tyrosine kinase inhibitor-resistant chronic myeloid leukemia.

    abstract::Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid leukemia (CML). However, resistance is occasionally observed, mainly due to mutations within the BCR-ABL kinase domain. The T315I substitution confers complete resistance to all TKIs commonly used in clinical practice. To date, the ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2010.520774

    authors: Chomel JC,Sorel N,Bonnet ML,Bertrand A,Brizard F,Roy L,Guilhot F,Turhan AG

    更新日期:2010-11-01 00:00:00

  • Acute myeloid leukemia outcome: role of nucleotide excision repair polymorphisms in intermediate risk patients.

    abstract::In acute myeloid leukemia (AML), cytogenetics predicts treatment outcome for the favorable and poor subgroups but not for the intermediate subgroup. Polymorphisms within the nucleotide excision repair (NER) pathway may lead to interindividual differences in DNA repair capacity, influencing outcome. We studied the role...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190903582804

    authors: Strom SS,Estey E,Outschoorn UM,Garcia-Manero G

    更新日期:2010-04-01 00:00:00

  • Treatment of Waldenstrom's macroglobulinemia with the combination of fludarabine and cyclophosphamide.

    abstract::Fludarabine is an active agent for the treatment of Waldenstrom's macroglobulinemia (WM) and its combination with cyclophosphamide has been effective in many patients with low-grade lymphoma and chronic lymphocytic leukemia. Based on these data, we administered the combination of fludarabine (25 mg/m2 i.v. day 1-3) an...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.1080/1042819031000077025

    authors: Dimopoulos MA,Hamilos G,Efstathiou E,Siapkaras I,Matsouka C,Gika D,Grigoraki V,Papadimitriou C,Mitsibounas D,Anagnostopoulos N

    更新日期:2003-06-01 00:00:00

  • Serum cytokine levels in infectious mononucleosis at diagnosis and convalescence.

    abstract::Infection with the Epstein-Barr virus (EBV) is common worldwide. A significant number of infected individuals develop infectious mononucleosis (IM). IM is manifested in most patients as a benign disease with mild symptoms. However, serious complications may develop in a subset of patients. Because EBV-infected B lymph...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199809057570

    authors: Wright-Browne V,Schnee AM,Jenkins MA,Thall PF,Aggarwal BB,Talpaz M,Estrov Z

    更新日期:1998-08-01 00:00:00

  • Monoclonal B-cell lymphocytosis: a reappraisal of its clinical implications.

    abstract::Monoclonal B-cell lymphocytosis (MBL) is a recently defined medical condition that displays biological similarities to chronic lymphocytic leukemia (CLL), the most common subtype of adult leukemia in the Western world. MBL may be diagnosed in individuals with a normal lymphocyte count via a screening assay (screening ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2012.666542

    authors: Molica S,Mauro FR,Molica M,Del Giudice I,Foà R

    更新日期:2012-09-01 00:00:00

  • Daratumumab for the treatment of AL amyloidosis.

    abstract::Autologous stem cell transplantation (ASCT) has been used as treatment for immunoglobulin light-chain (AL) amyloidosis for over two decades with improving outcomes; however, the majority of patients are not candidates for this therapy at diagnosis. Novel agents such as immunomodulatory drugs, proteasome inhibitors, an...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428194.2018.1485914

    authors: Sidiqi MH,Gertz MA

    更新日期:2019-02-01 00:00:00

  • Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group.

    abstract::Only 50% of patients with relapsed Hodgkin lymphoma (HL) can be cured with intensive induction chemotherapy, followed by high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT). Based on the results of the HDR2 trial two courses of DHAP and subsequent HDCT/ASCT are the current standard of care in rela...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.3109/10428194.2015.1083561

    authors: Sasse S,Alram M,Müller H,Smardová L,Metzner B,Doehner H,Fischer T,Niederwieser DW,Schmitz N,Schäfer-Eckart K,Raemaekers JM,Schmalz O,Tresckow BV,Engert A,Borchmann P

    更新日期:2016-05-01 00:00:00

  • Triptolide, a novel immunosuppressive and anti-inflammatory agent purified from a Chinese herb Tripterygium wilfordii Hook F.

    abstract::Triptolide is a diterpenoid triepoxide purified from a Chinese herb Tripterygium Wilfordii Hook F (TWHF). TWHF has been used in traditional Chinese medicine for more than two thousand years. However, its potential value was recognized by the western medicine only after investigators observed the effectiveness of TWHF ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428190109064582

    authors: Chen BJ

    更新日期:2001-07-01 00:00:00

  • Appraisal of the MTT-based assay as a useful tool for predicting drug chemosensitivity in leukemia.

    abstract::The MTT-based assay relies upon the cellular reduction of tetrazolium salts to their intensely colored formazans. The test is easy to perform in hematological malignancies and is adaptable for high throughput of samples, although there are some minor limitations in its application resulting from metabolic interference...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/1042819031000116607

    authors: Hayon T,Dvilansky A,Shpilberg O,Nathan I

    更新日期:2003-11-01 00:00:00

  • The associations of Janus kinase-2 (JAK2) A830G polymorphism and the treatment outcomes in patients with acute myeloid leukemia.

    abstract::The Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway is active in both normal hematopoiesis and hematological malignancies. Moreover, Janus kinase-2 (JAK2) is the key hematopoietic kinase, and mutations together with single nucleotide polymorphisms (SNPs) of JAK2 have been thoroughly ev...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.3109/10428191003774960

    authors: Zhong Y,Chen B,Feng J,Cheng L,Li Y,Qian J,Ding J,Gao F,Xia G,Chen N,Lu Z

    更新日期:2010-06-01 00:00:00